Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0599766 (functional recovery)
 13,441 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Treatment with gangliosides or thyrotropin-releasing hormone has been shown to stimulate structural and functional recovery that follows mechanical or chemical lesions in the nervous system. We studied the possible effects of the ganglioside GM1 and thyrotropin-releasing hormone on the survival rate of spinal motorneurons after sciatic nerve transection at the age of 1 week in the rat. GM1 (30 mg/kg body weight, i.p.) was administered 24 and 1 h before and once daily for 2 weeks after transection. TRH (2 mg/kg body weight, i.p.) was administered 1 h before, at 2, 16, and 24 h, and thereafter once daily for 7 days after transection. Nine weeks postlesion, the number of motorneuron profiles labeled by retrograde transport from the proximal stump of the sciatic nerve was counted and measured using a computerized image analysis system, and the number of myelinated axons in ventral roots L4 and L5 was estimated. Compared with controls, no significant effects of GM1 or hormone treatment were observed with regard to the number, diameter, and area of motorneuron profiles and the number of ventral root myelinated axons ipsilateral to sciatic nerve injury. The results may indicate principal differences between various lesions and/or metabolic reactions following a lesion of developing and adult neurons. The present lesion model with an intense axon reaction and extensive nerve cell death does not seem to respond to administration of exogenous GM1 or thyrotropin-releasing hormone.
 ...
PMID:Exogenous GM1 ganglioside and thyrotropin-releasing hormone do not affect survival rate of spinal motorneurons and number of ventral root myelinated fibers following early postnatal sciatic nerve transection. 312 77

The changes in acetylcholine release from the cerebral cortex induced by a unilateral electrolytic lesion of the nucleus basalis and by a treatment with GM1 monosialoganglioside (30 mg/kg i.p. for 20 days) were investigated. Acetylcholine release was measured using the cortical cup technique in rats transected at midpontine level. In the lesioned rats treated with saline an ipsilateral 38% decrease in acetylcholine release was observed. GM1 treatment prevented the decrease and brought about a 30% contralateral increase. These results indicate that GM1 induces a functional recovery of the cholinergic neurons ascending to the cortex.
 ...
PMID:Recovery of cortical acetylcholine output after ganglioside treatment in rats with lesion of the nucleus basalis. 358 37

Postsurgical injections of GM1 gangliosides (30 mg/kg IP) reduced neither behavioral deficits in rats following bilateral ablation of the visual cortex nor the extent of retrograde degeneration of neurons in the dorsolateral geniculate nucleus that typically accompanies large lesions of the visual cortex. Our findings are in contrast to previous research, in which ganglioside treatments have been shown to enhance the rate of functional recovery after lesions in other parts of the central nervous system. The negative findings in the present experiment may be due to the disruption of normal circadian rhythms caused by occipital cortex injury.
 ...
PMID:Gangliosides fail to enhance behavioral recovery after bilateral ablation of the visual cortex. 362 4

Adult male Fischer-344 rats were given bilateral injections of 2.5 micrograms colchicine or artificial cerebrospinal fluid into caudal and rostral sites of the dentate gyrus of the hippocampus. One group of rats received 21 consecutive daily injections of 20 mg/kg GM1 gangliosides, i.p., beginning the day prior to surgery. Another group received saline. Colchicine-induced hypermotility was not seen in animals repeatedly handled 21 d after surgery, in spite of significant decreases in granule cell number and decreases in the volume of hippocampal mossy fibers. Pretreatment with GM1 had no effect on behavior and it did not protect against the hippocampal damage produced by colchicine. Rats given colchicine, but not handled for 21 d, showed significant hypermotility, which was associated with decreases in hippocampal granule cells. These data underscore the importance of handling in postlesion functional recovery.
 ...
PMID:Experiential factors in the expression of hypermotility produced by intradentate colchicine: lack of effect of GM1 ganglioside on colchicine-induced loss of granule cells and mossy fibers. 362 5

The partial lesion paradigm of the dorsal hippocampal afferents in the rat was used as a model to study the effect of GM1 ganglioside treatment on recovery of neurotransmitter markers of the cholinergic and serotoninergic activity in various hippocampal regions. It was found that the enhancement of recovery of acetylcholinesterase, choline acetyltransferase and serotonin uptake by GM1 treatment (30 mg/kg i.m., daily), as studied on the 6th and 21st postlesion day, was dependent on the degree of fiber degeneration. The results may be interpreted in terms of the relationship between the action of GM1 and that of neuronotrophic factors whose release also depends on the extent of the fiber degeneration. These data indicate that GM1 elicits the recovery of biochemical parameters, or fails to, depending on the specificity of the trauma. The result may explain why, after certain brain lesions, GM1 does not promote functional recovery.
 ...
PMID:The effect of GM1 ganglioside on cholinergic and serotoninergic systems in the rat hippocampus following partial denervation is dependent on the degree of fiber degeneration. 373 Aug 33

In the present study the topology and the biochemical mechanisms underlying the functional recovery of the dopaminergic nigrostriatal system is further analyzed. Rats with unilateral hemitransection were treated with 30 mg/kg GM1 monosialoganglioside or with its internal ester derivative for different periods of time. GM1 enhances 3H-dopamine uptake in striatal synaptosomes of the lesioned side, and the enhancement of dopamine uptake precedes that of striatal tyrosine hydroxylase activity. The above biochemical effects are accompanied by changes in behavioral- and electrophysiological-related parameters. The effect of GM1 on striatal tyrosine hydroxylase of the lesioned side disappears when the ascending dopaminergic fibers are extensively lesioned. This suggests that the source of regrowing dopaminergic nerve terminals in the striatum of partially lesioned rats resides mainly in the intact axons remaining in the ipsilateral side. When GM1 is injected into partially lesioned rats kept in darkness, no effect on tyrosine hydroxylase activity is observed. This indicates that the mechanism through which GM1 acts involves a normal light-dark cycle.
 ...
PMID:The functional recovery of damaged brain: the effect of GM1 monosialoganglioside. 615 Jan 19

Reports indicate that exogenous gangliosides can accelerate neurite outgrowth in vitro and facilitate peripheral nerve regeneration in vivo. An experiment was designed to assess whether ganglioside administration alters functional recovery and neuronal regeneration after a CNS lesion. Rats trained on an alternation behavior and subjected to a unilateral entorhinal cortical lesion were given daily (i.m.) injections of either total brain ganglioside or GM1 ganglioside. Results show that ganglioside administration reduces the extent of behavioral deficit caused by the lesions and facilitated the course of functional recovery. It is hypothesized that gangliosides are enhancing hippocampal sprouting which occurs subsequent to the entorhinal lesion.
 ...
PMID:Exogenous gangliosides enhance recovery from cns injury. 674 42

Gangliosides, including GM1, provide a measure of improved functional recovery after ischemic, toxic, and traumatic brain injuries in animal studies. Since systemically injected GM1 has provided equivocal results in a variety of human neurodegenerative conditions, the possibility exists that intrathecal or intracerebroventricular delivery might provide more effective concentrations along the neuroaxis. In preparation to consider clinical trials, the potential neurotoxicologic effects of chronic intrathecal GM1 were studied in ewes. Preliminary in vitro tests first demonstrated the stability and compatibility of GM1 in implanted pumps. Two groups of adult ewes were then implanted with either Therex or Infusaid continuous flow implantable pumps and chronic intrathecal catheters. Ewes were infused intrathecally with either preservative-free normal saline (n = 5) or GM1 (n = 7) 100 micrograms-10,000 micrograms/d for up to 24 wk. No abnormal behavioral responses were noted. Cerebrospinal fluid analyzed for GM1 concentrations by thin layer chromatography revealed no evidence of GM1 accumulation. After the animals were killed, spinal cords were removed, fixed, sectioned, and stained. Histologic analysis revealed no generalized pattern of neuronal damage, demyelination, gliosis, or axonopathy to distinguish intrathecal normal saline or GM1. In both treated and control groups, the only consistent finding was a pericatheter-associated compression of white matter with axonal dilation, vacuolation, and occasional neuronal loss. Catheter tracts in both groups were also associated with variable leptomeningeal fibroproliferative changes in adjacent dura and pia, at times in conjunction with more generalized duromeningeal thickening. In summary, chronic intrathecal GM1 in doses up to 10 mg/d had no definable neuropathologic consequences.
 ...
PMID:Neurotoxicology of chronic infusion of the ganglioside GM1 in the ewe: phase I. intrathecal administration. 769 Jan 99

The monosialoganglioside GM1 is a compound with neurotrophic properties found to foster functional recovery in various paradigms of brain damage. The present experiment examined whether systemic treatment with GM1 may facilitate behavioral recovery in rats with fimbria-fornix lesions and intrahippocampal grafts rich in cholinergic neurons. Among 68 Long-Evans female rats, 46 sustained a bilateral electrolytic lesion of the fimbria and the dorsal fornix and 22 were sham-operated. Fourteen days later, half the lesioned rats were subjected to intrahippocampal grafts of a fetal septal cell suspension. Starting a few hours after lesion surgery and over a 2-month period, half the rats of each surgical treatment group received a daily injection of GM1 (30 mg/kg i.p.), the other half being injected with saline as a control. All rats were subsequently tested for locomotor activity and radial maze learning. The lesions induced locomotor hyperactivity and impaired learning performances in both an uninterrupted and an interrupted radial maze testing procedure. In all rats with surviving grafts, the grafts had provided the hippocampus with a new and dense organotypic acetylcholinesterase-positive innervation pattern which did not differ between saline- and GM1-treated subjects. The scores/performances of the rats that had received only the grafts or only the GM1 treatment did not differ significantly from those of their respective lesion-only counterparts. However, in the radial-arm maze task, the grafted rats given GM1 showed improved learning performances as compared with their saline-treated counterparts: they used more efficient visit patterns under the uninterrupted testing conditions and made fewer errors under the interrupted ones. The results suggest that GM1 treatment or intrahippocampal grafts used separately do not attenuate the lesion-induced behavioral deficits measured in this experiment. However, when GM1 treatment and grafts are used conjointly, both may interact in a manner allowing part of these deficits to be attenuated.
 ...
PMID:Behavioral effects of GM1 ganglioside treatment and intrahippocampal septal grafts in rats with fimbria-fornix lesions. 926 7

Administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to cats results in a parkinsonian syndrome characterized by rigidity, akinesia, bradykinesia, decreased response to external sensory stimuli and depletion of nigrostriatal dopamine. Cats spontaneously recover gross sensorimotor functions despite little recovery of the dopaminergic innervation of the striatum. In contrast, GM1 ganglioside administration accelerates gross behavioral recovery and causes an increased dopaminergic innervation of the striatum. This study examined whether these two recovery conditions are characterized by different degrees of functional recovery. Cats were trained to perform a sensorimotor reaching task prior to MPTP exposure and were then re-tested on the task 6 weeks later after spontaneously recovering gross motor functioning or after 6 weeks of GM1 treatment. Gross motor recovery was similar in both groups. However, the spontaneously recovered cats had significant difficulty in performing the task while GM1-treated cats performed normally. GM1-treated cats also had significant increases in striatal [3H]mazindol binding compared to spontaneously recovered cats. These results suggest that while gross motor functions may improve to a similar extent with spontaneous and GM1-induced recovery from experimental parkinsonism, complex sensorimotor behavior recovers to different extents under the different recovery conditions. More complete behavioral recovery may depend upon at least a partial recovery of striatal dopaminergic terminals rather than neurochemical compensation.
 ...
PMID:Differential recovery of sensorimotor function in GM1 ganglioside-treated vs. spontaneously recovered MPTP-treated cats: partial striatal dopaminergic reinnervation vs. neurochemical compensation. 982 74


<< Previous 1 2 3 Next >>